Presentation Explores Targeted 308-nm Excimer Laser's Role in Expanding Treatment Options for Patients with Localized Inflammatory and Autoimmune Skin Diseases

演讲探讨靶向308纳米准分子激光在扩大局限性炎症性和自身免疫性皮肤病患者治疗选择中的作用

HORSHAM, Pa.

宾夕法尼亚州霍舍姆

,

，

Oct. 9, 2026

2026年10月9日

/PRNewswire/ -- STRATA Skin Sciences, Inc. ('STRATA' or the 'Company'), a global leader in excimer laser therapy dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced its presentation of seven illustrative cases on targeted 308-nm excimer laser phototherapy for localized and inflammatory autoimmune skin diseases at the 2026 Fall Clinical Dermatology Conference, taking place October 8-11, 2026 in Las Vegas..

/PRNewswire/ -- STRATA Skin Sciences, Inc.（“STRATA”或“公司”）是一家全球领先的准分子激光疗法企业，致力于开发、商业化及推广用于治疗皮肤病的创新产品。该公司今日宣布，在2026年秋季临床皮肤科大会（2026年10月8日至11日于拉斯维加斯举行）上，展示了七个关于靶向308纳米准分子激光光疗治疗局部性和炎症性自身免疫性皮肤病的典型病例。

'We are pleased to have the opportunity to present our findings at Fall Clinical and highlight the impact excimer laser phototherapy can have in addressing skin diseases that can be challenging to treat with topical therapies alone,' said Erica Jordan, CEO, STRATA Skin Sciences. 'These cases contribute to the ongoing conversation around personalized, evidence-based approaches to inflammatory and autoimmune skin diseases, while generating the data and insights needed to help providers deliver meaningful, even life-changing outcomes for their patients.'.

STRATA Skin Sciences 首席执行官 Erica Jordan 表示：“我们很高兴有机会在秋季临床大会（Fall Clinical）上展示我们的研究成果，并强调准分子激光光疗在治疗仅靠外用疗法难以应对的皮肤疾病方面所能产生的影响。这些病例有助于推动关于炎症性和自身免疫性皮肤病的个性化、循证方法的持续讨论，同时生成帮助医疗提供者为患者带来有意义、甚至改变生命的治疗结果所需的数据和见解。”

Key findings from STRATA's 2026 Fall Clinical Dermatology Conference poster presentation – titled 'Targeted 308-nkm Excimer Laser Phototherapy for Localized Inflammatory and Autoimmune Skin Diseases: An Illustrative Case Series' and authored by Suhail Hadi, MD and Mark F. Lebwohl, MD – include:

STRATA 2026年秋季临床皮肤病学大会海报展示（题为《靶向308纳米准分子激光光疗治疗局限性炎症性和自身免疫性皮肤病：一例系列病例 illustration》）的主要发现，由Suhail Hadi博士和Mark F. Lebwohl博士撰写，包括：

Targeted 308-nm excimer laser phototherapy produced high levels of re-pigmentation across seven distinct conditions – including psoriasis, atopic dermatitis, palmoplantar keratoderma, vitiligo, post-inflammatory hypopigmentation, alopecia areata, and mycosis fungoides – and multiple anatomic sites, such as the scalp, hands, feet, face, neck, forearm, and thigh..

靶向308纳米准分子激光光疗在七种不同疾病（包括银屑病、特应性皮炎、掌跖角化病、白癜风、炎症后色素减退、斑秃和蕈样肉芽肿）以及多个解剖部位（如头皮、手、足、面部、颈部、前臂和大腿）均产生了高水平的复色效果。

Responses were sustained through six months to two years in the patients with follow-up data, without systemic therapy and with no adverse events beyond transient erythema.

在具有随访数据的患者中，疗效维持了六个月至两年，期间未接受全身治疗，且除短暂性红斑外无其他不良事件。

Excimer laser phototherapy served as an option for patients where standard topical treatments had already failed, helping those who have struggled to find relief.

对于标准外用治疗已失败的患者，准分子激光光疗成为一种选择，帮助那些难以获得缓解的患者。

About STRATA Skin Sciences, Inc.

关于 STRATA Skin Sciences, Inc.

STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing, and marketing innovative products for the in-office treatment of various dermatologic conditions, such as psoriasis, vitiligo, atopic dermatitis, and acne. Its products include the XTRAC

STRATA Skin Sciences 是一家医疗技术公司，致力于开发、商业化及推广用于在诊室治疗各种皮肤病（如银屑病、白癜风、特应性皮炎和痤疮）的创新产品。其产品包括 XTRAC

®

注册商标

excimer laser, VTRAC

准分子激光，VTRAC

®

®

lamp systems, and the TheraClear

灯系统，以及 TheraClear

®

®

X Acne Therapy System. STRATA is proud to offer these exciting technologies in the U.S. through its unique Partnership Program. STRATA's popular partnership approach includes advertising assistance to help raise awareness and promote the program within practices.

X痤疮治疗系统。STRATA自豪地通过其独特的合作伙伴计划在美国提供这些令人振奋的技术。STRATA广受欢迎的合作方式包括提供广告支持，以帮助提高知名度并在医疗机构内推广该计划。

Safe Harbor

安全港

This press release includes 'forward-looking statements' within the meaning of the Securities Litigation Reform Act of 1995. These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such statements. STRATA Skin Sciences undertakes no obligation to publicly update or revise any forward-looking statements..

本新闻稿包含1995年《私人证券诉讼改革法案》意义上的“前瞻性陈述”。这些陈述涉及已知和未知的风险与不确定性，可能导致实际结果与此类陈述所表达或暗示的结果存在重大差异。STRATA Skin Sciences不承担公开更新或修订任何前瞻性陈述的义务。

Contact: EvolveMKD,

联系人：EvolveMKD，

[email protected]

[email protected]

SOURCE STRATA Skin Sciences, Inc.

来源：STRATA Skin Sciences, Inc.

21

二十一

%

百分比

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示